Literature DB >> 15290153

Characteristics of patients with a favorable natural course of myopic choroidal neovascularization.

Kengo Hayashi1, Kyoko Ohno-Matsui, Takeshi Yoshida, Kanako Kobayashi, Ariko Kojima, Noriaki Shimada, Kenjiro Yasuzumi, Soh Futagami, Takashi Tokoro, Manabu Mochizuki.   

Abstract

OBJECTIVE: To identify the characteristics of patients with myopic choroidal neovascularization (CNV) who had a favorable visual prognosis without treatment.
METHODS: We reviewed the medical records of 52 consecutive patients (57 eyes) with myopic CNV who were followed for at least 5 years after the onset of CNV. Clinical characteristics (patient age, CNV size and location, visual acuity at onset, chorioretinal atrophy development around CNV, and degree of myopia) were compared between patients whose visual acuity 5 years after CNV onset was better than 20/40 and those whose visual acuity was worse than 20/200.
RESULTS: Among 57 eyes, eight eyes (14.0%; 8 patients) had a final visual acuity better than 20/40. On the other hand, 37 eyes (64.9%; 33 patients) had a final visual acuity worse than 20/200. Statistical analysis revealed that the patients with a good prognosis (final visual acuity better than 20/40) were significantly younger, had significantly smaller CNV, and significantly better initial visual acuity (Mann-Whitney U-test, p<0.05). Juxtafoveal CNV was more frequently observed in patients with a good prognosis than in those with a poor prognosis (Fisher's exact probability test, p<0.05). Only one patient (12.5%) in the good prognosis group developed a very limited area of chorioretinal atrophy around the regressed CNV, while 91.9% of the patients in the poor prognosis group developed chorioretinal atrophy. Refractive status and the axial length measurements did not differ between the two groups.
CONCLUSIONS: Some young patients with myopic CNV retain favorable vision over the long term without active treatment. These information might be useful to predict the visual outcome of patients with myopic CNV.

Entities:  

Mesh:

Year:  2004        PMID: 15290153     DOI: 10.1007/s00417-004-0960-5

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  18 in total

Review 1.  Ocular fluorometry: principles, fluorophores, instrumentation, and clinical applications.

Authors:  F Docchio
Journal:  Lasers Surg Med       Date:  1989       Impact factor: 4.025

2.  Inward and outward permeability of the blood-retinal barrier in experimental myopia.

Authors:  A Yoshida; S Ishiko; M Kojima
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-08       Impact factor: 3.117

3.  Pathologic myopia and choroidal neovascularization.

Authors:  M L Hotchkiss; S L Fine
Journal:  Am J Ophthalmol       Date:  1981-02       Impact factor: 5.258

4.  On the definition of pathologic myopia in group studies.

Authors:  T Tokoro
Journal:  Acta Ophthalmol Suppl       Date:  1988

5.  Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization.

Authors:  H Tabandeh; H W Flynn; I U Scott; M L Lewis; P J Rosenfeld; F Rodriguez; A Rodriguez; L J Singerman; J Schiffman
Journal:  Ophthalmology       Date:  1999-11       Impact factor: 12.079

6.  Etiology of choroidal neovascularization in young patients.

Authors:  S Y Cohen; A Laroche; Y Leguen; G Soubrane; G J Coscas
Journal:  Ophthalmology       Date:  1996-08       Impact factor: 12.079

7.  Pathogenesis of laser-induced choroidal subretinal neovascularization.

Authors:  H Miller; B Miller; T Ishibashi; S J Ryan
Journal:  Invest Ophthalmol Vis Sci       Date:  1990-05       Impact factor: 4.799

8.  Subretinal hemorrhages with or without choroidal neovascularization in the maculas of patients with pathologic myopia.

Authors:  S Hayasaka; M Uchida; T Setogawa
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

9.  Myopic choroidal neovascularization: a 10-year follow-up.

Authors:  Takeshi Yoshida; Kyoko Ohno-Matsui; Kenjiro Yasuzumi; Ariko Kojima; Noriaki Shimada; Soh Futagami; Takashi Tokoro; Manabu Mochizuki
Journal:  Ophthalmology       Date:  2003-07       Impact factor: 12.079

10.  Prevalence of myopia in the United States.

Authors:  R D Sperduto; D Seigel; J Roberts; M Rowland
Journal:  Arch Ophthalmol       Date:  1983-03
View more
  16 in total

1.  Outcome of photodynamic therapy in choroidal neovascularization due to pathologic myopia and related factors.

Authors:  Tugrul Altan; Nur Acar; Ziya Kapran; Yaprak B Unver; Sezin Ozdogan
Journal:  Int Ophthalmol       Date:  2012-02-19       Impact factor: 2.031

Review 2.  Choroidal neovascularisation in pathological myopia: an update in management.

Authors:  W-M Chan; M Ohji; T Y Y Lai; D T L Liu; Y Tano; D S C Lam
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

3.  Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia.

Authors:  Ariko Kojima; Kyoko Ohno-Matsui; Satoshi Teramukai; Yoko Ishihara; Noriaki Shimada; Takeshi Yoshida; Yoshiharu Sugamoto; Takashi Tokoro; Manabu Mochizuki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-04-21       Impact factor: 3.117

4.  Photodynamic therapy in non-subfoveal choroidal neovascularization secondary to pathological myopia: 1-year outcome.

Authors:  Juan Reche-Frutos; Cristina Calvo-González; Juan Donate-López; Julián García-Feijoó; M Wasfy; F Saenz-Frances; C Fernandez-Perez; J Garcia-Sanchez
Journal:  Br J Ophthalmol       Date:  2007-12       Impact factor: 4.638

5.  Choroidal neovascularization secondary to pathological myopia-macular Bruch membrane defects as prognostic factor to anti-VEGF treatment.

Authors:  João Coelho; André Ferreira; Ana Carolina Abreu; Sílvia Monteiro; Maria João Furtado; Miguel Gomes; Miguel Lume
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-03-21       Impact factor: 3.117

6.  Epidemiology, treatment pattern and health care utilization of myopic choroidal neovascularization: a population based study.

Authors:  Ming-Chin Yang; Yen-Po Chen; Elise Chia-Hui Tan; Claudia Leteneux; Erin Chang; Carol Hy Chu; Chi-Chun Lai
Journal:  Jpn J Ophthalmol       Date:  2017-01-06       Impact factor: 2.447

7.  Long-term outcomes of myopic choroidal neovascularisation treated with combined ranibizumab and dexamethasone characterised by multi-modal imaging.

Authors:  Anna C S Tan; Kelvin Teo; Ong Sze Guan; Adrian Koh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-03-12       Impact factor: 3.117

Review 8.  Recent trends in the management of maculopathy secondary to pathological myopia.

Authors:  D Mitry; H Zambarakji
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-12-13       Impact factor: 3.117

9.  Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization.

Authors:  H Nakanishi; A Tsujikawa; Y Yodoi; Y Ojima; A Otani; H Tamura; K Yamashiro; S Ooto; N Yoshimura
Journal:  Eye (Lond)       Date:  2011-01-21       Impact factor: 3.775

10.  Indocyanine green angiographic features of myopic subfoveal choroidal neovascularization as a prognostic factor after photodynamic therapy.

Authors:  Suk Ho Byeon; Oh Woong Kwon; Sung Chul Lee; Sung Soo Kim; Hyoung Jun Koh
Journal:  Korean J Ophthalmol       Date:  2006-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.